What is dolutegravir (DTG) and why is this HIV drug so important to global HIV programming?
Dolutegravir (DTG) is a drug used to treat HIV infection. DTG is one of several antiretrovirals included in the “integrase inhibitor” drug class. DTG, when combined with 2 other medicines in a single fixed-dose combination pill, is considered to be among the best current treatments for HIV, but its availability has previously been limited due to high cost.
However, the predicted price reductions announced today for the fixed-dose combination of tenofovir/lamivudine/dolutegravir (TLD) to an average price of US$ 75 per patient per year will make DTG-containing ARV treatment regimens affordable for many low- and middle-income countries.